Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-181b
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
CYLD
Cancer name
Pancreatic Cancer
Cancer site
Pancreas
Treatment type
Chemotherapy
Drug
Gemcitabine
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
The present study demonstrated that miR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine, and verified that miR-181b enhances the activity of NF-ĪŗB by inhibiting CYLD, leading to the resistance to gemcitabine.
Tissue resource
pancreatic cancer cell lines BxPC3
pancreatic cancer cell lines MiaPaCa2
pancreatic cancer cell lines Panc1
pancreatic cancer cell lines PSN1
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Japan Cancer Research Resources Bank
Country
Japan
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.